|
|||||
|
|
Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial |
|
| Authors: | Darrel A. Cook Mel Krajden Adam R. Brentnall Lovedeep Gondara Tracy Chan Jennifer H. Law Laurie W. Smith Dirk J. van Niekerk Gina S. Ogilvie Andrew J. Coldman Rhian Warman Caroline Reuter Jack Cuzick Attila T. Lorincz |
| Affiliation: | 1. BC Centre for Disease Control, Vancouver, British Columbia, Canada;2. BC Centre for Disease Control, Vancouver, British Columbia, Canada Lower Mainland Pathology and Laboratory Medicine, Vancouver, British Columbia, Canada Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada;3. Wolfson Institute of Preventive Medicine, Centre for Cancer Prevention, Queen Mary University of London, London, United Kingdom;4. BC Cancer Agency, Vancouver, British Columbia, Canada;5. Lower Mainland Pathology and Laboratory Medicine, Vancouver, British Columbia, Canada;6. BC Cancer Agency, Vancouver, British Columbia, Canada Lower Mainland Pathology and Laboratory Medicine, Vancouver, British Columbia, Canada Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada |
| Abstract: | Human papillomavirus (HPV)-based cervical cancer screening requires triage of HPV positive women to identify those at risk of cervical intraepithelial neoplasia grade 2 (CIN2) or worse. We conducted a blinded case–control study within the HPV FOCAL randomized cervical cancer screening trial of women aged 25–65 to examine whether baseline methylation testing using the S5 classifier provided triage performance similar to an algorithm relying on cytology and HPV genotyping. Groups were randomly selected from women with known HPV/cytology results and pathology outcomes. Group 1: 104 HPV positive (HPV+), abnormal cytology (54 CIN2/3; 50 |
| Keywords: | human papillomavirus methylation cervical cancer screening colposcopy triage cervical cancer |